|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02219 CHAOJU EYE CARE
Nominal 
2.570 -0.030 (-1.154%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,405,454 | 2.625% | 1,369,505 | 990,044 | 997,787 | 794,282 |
| Cost of Sales | (794,152) | 6.117% | (748,371) | (555,347) | (549,113) | (444,762) |
| Gross Profit | 611,302 | -1.583% | 621,134 | 434,697 | 448,674 | 349,520 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (2,028) | -65.244% | (5,835) | (3,957) | (13,608) | (12,165) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 262,723 | -12.204% | 299,242 | 239,138 | 210,582 | 157,621 | |
| Taxation | (76,513) | -2.540% | (78,507) | (55,942) | (52,941) | (37,090) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 8,866 | 8.400% | 8,179 | 4,556 | 4,108 | 3,608 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 195,076 | -14.782% | 228,914 | 187,752 | 161,749 | 124,139 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (28,930) | -0.533% | (29,085) | (11,077) | 2,218 | 8,152 |
| Depreciation & Amortisation | 144,161 | 16.861% | 123,361 | 99,366 | 83,522 | 77,251 |
| Directors' Emoluments | 6,664 | 10.827% | 6,013 | 4,323 | 5,161 | 3,242 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 28.000 | -15.152% | 33.000 | 27.000 | 26.000 | 23.000 |
| DPS (cts) | 23.074 | -- | 26.984 | 15.227 | 8.478 | -- |
| Dividend Payout Ratio (%) | 82.405% | -- | 81.770% | 56.396% | 32.609% | -- |
| Cash flow per share ($) | 0.514 | -- | 0.536 | 0.387 | 0.399 | 0.452 |
| NBV per share ($) | 3.272 | -- | 3.335 | 3.212 | 2.976 | -- |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 113,643 |
| %Change | -16.716% |
| EPS / (LPS) | RMB 0.160 |
| NBV Per Share (¥) | RMB 3.326 |